Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Addition of MK-0431 (sitagliptin) to pioglitazone in type 2 diabetes mellitus
2004-000311-26Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jun 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Pioglitazone + MK-0431 with Pioglitazone + placebo (2 arms). Primary endpoints: HbA1c change from baseline at 24 weeks and Safety and tolerability of MK-0431. Started Jun 2004; status: completed.
02
Drugs
sitagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2004-000311-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000311-26.